Modality
Vaccine
MOA
EGFRi
Target
PRMT5
Pathway
Innate Imm
CTCLHS
Development Pipeline
Preclinical
~May 2014
→ ~Aug 2015
Phase 1
~Nov 2015
→ ~Feb 2017
Phase 2
~May 2017
→ ~Aug 2018
Phase 3
Nov 2018
→ Apr 2027
Phase 3Current
NCT07204584
2,699 pts·HS
2024-10→2027-04·Terminated
NCT05516061
1,845 pts·HS
2024-05→TBD·Completed
NCT03856432
548 pts·CTCL
2020-04→2027-01·Terminated
+1 more trial
7,452 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-01-129mo awayPh3 Readout· CTCL
2027-04-091.0y awayPh3 Readout· HS
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P3
Active
P3
Termina…
P3
Complet…
P3
Termina…
Catalysts
Ph3 Readout
2027-01-12 · 9mo away
CTCL
Ph3 Readout
2027-04-09 · 1.0y away
HS
ActiveCompletedTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07204584 | Phase 3 | HS | Terminated | 2699 | VA |
| NCT05516061 | Phase 3 | HS | Completed | 1845 | FEV1 |
| NCT03856432 | Phase 3 | CTCL | Terminated | 548 | SRI-4 |
| NCT07261753 | Phase 3 | HS | Active | 2360 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 |